Niagen Bioscience (NASDAQ:NAGE - Get Free Report) was downgraded by Wall Street Zen from a "strong-buy" rating to a "buy" rating in a report released on Friday.
A number of other equities analysts have also weighed in on NAGE. Canaccord Genuity Group started coverage on shares of Niagen Bioscience in a research report on Tuesday, May 27th. They set a "buy" rating and a $13.00 target price for the company. Roth Capital increased their target price on shares of Niagen Bioscience from $10.00 to $23.00 and gave the stock a "buy" rating in a research report on Friday.
Check Out Our Latest Analysis on NAGE
Niagen Bioscience Price Performance
NASDAQ NAGE traded up $0.48 on Friday, hitting $13.43. 1,329,467 shares of the stock traded hands, compared to its average volume of 854,919. The stock's fifty day simple moving average is $8.69. Niagen Bioscience has a 12 month low of $2.31 and a 12 month high of $13.53. The company has a market cap of $1.06 billion, a price-to-earnings ratio of 79.00 and a beta of 2.08.
About Niagen Bioscience
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
See Also
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
